

ReSearch Pharmaceutical Services, Inc.
Grant of Options

ReSearch Pharmaceutical Services, Inc. (“RPS” or the “Company”), a leading provider of integrated clinical development outsourcing solutions to the bio-pharmaceutical industry, is pleased to announce that is granted stock options (the “Grant”) over a total of 10,000 shares of common stock to certain directors of the Company on August 15, 2008.

The stock options are exercisable at \$3.70 per share being the most recent executed trade as of the date of the grant August 15, 2008. The options will vest over the next three calendar years, with one third of the options being made available to the option holder each successive year. The fully vested options are exercisable at any time between August 15, 2011 and August 15, 2018 being a period of between three and ten years from the date of grant.

The Grant has been made to the following RPS directors:

Jack Dean, Non-executive Director	5,000
Warren Myers, Non-executive Director	5,000

Following the Grant each of Jack Dean and Warren Myers hold options totaling 5,000 shares each and are not holding any other share amounts of RPS common stock.

For further information please contact:

ReSearch Pharmaceutical Services, Inc.:

Daniel M. Perlman, Chairman & Chief Executive Officer

Steven Bell, Chief Financial Officer

+1-215-540-0700

Nominated Adviser and UK Broker:

Arbuthnot Securities Limited

James Steel/Richard Tulloch

+44-20-7012-2100